ClinicalTrials.gg
RecruitingNCT07563738TEADCOUpdated Nov 5, 2026

A 2-part Phase 1/2 Open-label Trial on ODM-212

A Phase 1/2 interventional study of ODM-212 and Ipilimumab and nivolumab in Mesothelioma, Pancreatic Cancer and NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Orion Corporation, Orion Pharma. Recruiting at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Orion Corporation, Orion Pharma · Phase 1/2, Interventional, and Treatment

How we know · 10 judgments

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 22, 2026First sites in 6 new countries21 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
229
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Mesothelioma with a site in Spain — 2 open to participants now, 8 under way, 1 of them phase 3. Mesothelioma · Spain.

Planned enrollment
7th of 22
229 · median 142
Started
2026
the only one that year
Phase 1/2
6 of 22
2 open now
Registered
22nd of 22
by date

Among the 22 studies in Mesothelioma with a site in Spain, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 1/2, and was the 22nd registered.

Mesothelioma

305 studies on the registry are indexed under Mesothelioma; 59 are open to participants now.

Browse Mesothelioma studies →

Open to participants now

2 of the 22 studies in Mesothelioma with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 47 Mesothelioma studies recruiting now, 32 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Mesothelioma with a site in Spain, or all of them as a file.
02

Study summary

An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)

03

Conditions studied

  • Mesothelioma
  • Pancreatic Cancer
  • NSCLC (Advanced Non-small Cell Lung Cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥18 years old.
  • Performance status 0-1 on the (ECOG) Performance Scale.
  • of >12 weeks, in the opinion of the investigator.
  • Ability to take oral medications and willing to record daily adherence to product.
  • Part 1: Participants with or cytologically confirmed advanced or , unresectable solid tumors and who are able and willing to receive one of the anti-cancer therapies studied in this trial according to the investigator.

    • Arm A: Participants with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma who are eligible to receive treatment with ipilimumab/nivolumab; participants must not have undergone surgical therapy for mesothelioma.
    • Arm B: Participants with histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas who are eligible to receive treatment with nab-paclitaxel and gemcitabine.
    • Arm C: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C-mutation, confirmed using a validated test, who have received the available treatment and who are eligible for a treatment with sotorasib and have not received a KRAS G12C inhibitor as prior treatment.

Part 2:

  • Ipilimumab/nivolumab cohort: Participants with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma who are eligible to receive a treatment with ipilimumab/nivolumab. Prior treatment with ipilimumab, nivolumab and/or other /PD-L1/CTLA-4 inhibitors for advanced or metastatic disease is not allowed.
  • Nab-paclitaxel/gemcitabine cohort: Participants with histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas who are eligible to receive a treatment with nab-paclitaxel and gemcitabine. Previous treatments with nab-paclitaxel and/or gemcitabine for metastatic disease are not allowed.
  • Sotorasib cohort, treatment naïve: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C-mutation, confirmed using a validated test, who are eligible for a treatment with sotorasib and have not received a KRAS G12C inhibitor as prior treatment.
  • Sotorasib cohort, pretreated: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C mutation, confirmed using a validated test, who have documented progression on a prior KRAS G12C inhibitor (approved or investigational).

    • Part 2 only: Participants must have by (RECIST) v. 1.1 (modified RECIST for MPM).
    • A recent (taken up to 1 year ago), representative tumour tissue sample (from primary tumour or from metastasis) must be available. Tissue must be a core needle , excisional or incisional biopsy. Biopsies of bone lesions that do not have a soft tissue component or decalcified bone tumour samples are also not acceptable.
    • Amenable for paired fresh tumour biopsy at screening period and on-treatment.

Exclusion criteria

Exclusion Criteria:

  • Other active within the previous 2 years except for basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast, for which the participants has completed curative therapy.
  • Prior chemotherapy, immunotherapy (, tumour vaccine, cytokine or growth factor given to control the cancer) or other anti-cancer therapy within less than 2 weeks before trial treatment administration.
  • Any persistent unresolved toxicity from previous anti-cancer therapies of Grade ≥ 2 (except for peripheral neuropathy, alopecia, endocrine disorders that are controlled with replacement hormone therapy and asymptomatic laboratory abnormalities). Ongoing treatments for previous cancers are allowed as concomitant treatments if they do not have direct anti-tumour effect on the index tumour (e.g. hormone-suppressing agents).
  • Prior definitive radiation therapy within less than 4 weeks and prior palliative radiotherapy within less than 2 weeks before trial treatment administration. Radiopharmaceuticals should be expected to have cleared sufficiently from the participant's body before trial treatment administration.
  • Participants with brain or subdural are not eligible, unless the metastases are asymptomatic and have been adequately treated with local therapy.
  • Any severe active infection within 1 week of trial enrolment.
  • Known positive tests for surface antigen or virus (HCV) RNA; known (HIV) infection. Screening test is not required unless participant has clinical findings suggestive of HIV, HBV or HCV infection.
  • Major surgery within 4 weeks before the first dose of trial treatment or minor surgery within 1 week (participant must also have recovered from any surgery-related toxicities to less than CTCAE Grade 2).
  • doses of systemic medications, such as or absorbed topical steroids (doses >10 mg/day prednisone or equivalent) within 2 days before trial treatment administration.
  • Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g. nausea, diarrhoea, or vomiting) that might impair the bioavailability of ODM-212.
  • Use of other medicinal products within 2 weeks or at least 5 half-lives (whichever is longer) before trial treatment administration, or any persistent unresolved toxicity from such treatment that, according to the judgement of the investigator, may pose a health risk for the participant, if taking part in the trial. For drugs such as investigational monoclonal antibodies with half-lives >10 days, at least 8 weeks is required. In addition, all visits (apart from survival follow-up) related to the use of another IMP must be completed before dosing with trial treatments may commence.
  • Use of any live or (e.g., intranasal influenza, measles, mumps, rubella, shingles, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines) within 28 days prior to the first dose of study drug.
  • Any abnormalities in rhythm, conduction, or morphology of resting ; e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 ms, a prolonged (QTcF/B >470 ms) as demonstrated by 2 out of 3 repeated ECG at screening, performed according to local practice. A history of risk factors for torsade de pointes (e.g. heart failure, hypokalaemia, family history of long QT Syndrome) or the use of drugs that prolong the QT interval and are clearly associated with a known risk of torsade de pointes, even when taken as recommended per Crediblemeds.org QTdrugs list.
  • Significant cardiovascular impairment: history of congestive heart failure of (NYHA) Class III-IV, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke, (LVEF) \<50%, cardiac arrhythmia requiring medical treatment (including oral anticoagulation) within 6 months prior to the first dose of trial treatment.
  • Female participants who are breastfeeding or pregnant at screening or baseline. A separate baseline assessment for pregnancy is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
229 participants (estimated)

Study arms

  • Experimental
    ODM-212 with ipilimumab/nivolumab in mesothelioma

    Drug: ODM-212 · Drug: Ipilimumab and nivolumab

  • Experimental
    ODM-212 with gemcitabine and nab-paclitaxel in PDAC

    Drug: ODM-212 · Drug: Gemcitabine and nab-paclitaxel

  • Experimental
    ODM-212 with sotorasib in NSCLC

    Drug: ODM-212 · Drug: sotorasib

Interventions

  • DrugODM-212

    ODM-212 40mg tablet

  • DrugIpilimumab and nivolumab

    Ipilimumab: 1 mg/kg administered intravenously over 30 minutes every 6 weeks. Nivolumab: 360 mg administered intravenously over 30 minutes every 3 weeks.

  • DrugGemcitabine and nab-paclitaxel

    Nab-paclitaxel 125 mg/m2 administered intravenously over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. Gemcitabine 1000 mg/m2 administered intravenously over 30 minutes immediately after the completion of nab-paclitaxel administration on days 1, 8 and 15 of each 28-day cycle

  • Sotorasib total daily dose of 960 mg taken orally q.d. every day of the 21-day cycle

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities and Adverse Events

    Incidence and severity of adverse events and clinical laboratory abnormalities

    Time frame: Through study completion, on average of 2 years

07

Study locations

23 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Sep 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
May 4, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added — first sites in Denmark, Finland, France, Spain, Switzerland and 1 more
All 6 countries

Denmark, Finland, France, Spain, Switzerland, United Kingdom

Show 21 added (6 Spain, 4 France, 3 United States, 3 United Kingdom, 2 Denmark, 2 Finland, 1 Switzerland)
  • Valkyrie Clinical Trials · Los Angeles, United States
  • UC Irvine Health · Orange, United States
  • START Dallas-Fort Worth · Fort Worth, United States
  • Aalborg Universitets hospital · Aalborg, Denmark
  • Rigshospitalet University · Copenhagen, Denmark
  • Helsinki University Hospital · Helsinki, Finland
  • Turku University Hospital · Turku, Finland
  • Institut Bergonie · Bordeaux, France
  • Marseille University Hospital Timone · Marseille, France
  • CHU de Poitiers · Poitiers, France
  • Gustave Roussy · Villejuif, France
  • HM Nou Delfos · Barcelona, Spain
  • ICO Hospitale · Barcelona, Spain
  • Vall D'Hebron University Hospital · Barcelona, Spain
  • HM Sanchinarro · Madrid, Spain
  • Hospital 12 de Octubre · Madrid, Spain
  • START Madrid FJD · Madrid, Spain
  • Ospedale Regionale Bellinzona · Bellinzona, Switzerland
  • Leicester Royal Infirmary · Leicester, United Kingdom
  • Royal Marsden Hospital · London, United Kingdom
  • University Hospital Southampton · Southampton, United Kingdom
Oct 22, 2026
Site contacts
Changed at 22 sites. See the sites
Show 22 sites
  • Valkyrie Clinical Trials · Los Angeles, United StatesContact d•••@valkyrieclinicaltrials.com→none listed
  • UC Irvine Health · Orange, United StatesContact f•••@hs.uci.edu→none listed
  • START Dallas-Fort Worth · Fort Worth, United StatesContact h•••@txcc.com→none listed
  • NEXT Oncology Virginia · Fairfax, United StatesContact a•••@nextoncology.com→none listed
  • Aalborg Universitets hospital · Aalborg, DenmarkContact w•••@rn.dk→none listed
  • Rigshospitalet University · Copenhagen, DenmarkContact k•••@regionh.dk→none listed
  • Helsinki University Hospital · Helsinki, FinlandContact k•••@hus.fi→none listed
  • Turku University Hospital · Turku, FinlandContact p•••@utu.fi→none listed
  • Institut Bergonie · Bordeaux, FranceContact v•••@bordeaux.unicancer.fr→none listed
  • Marseille University Hospital Timone · Marseille, FranceContact l•••@ap-hm.fr→none listed
  • CHU de Poitiers · Poitiers, FranceContact n•••@chu-poitiers.fr→none listed
  • Gustave Roussy · Villejuif, FranceContact a•••@gustaveroussy.fr→none listed
  • HM Nou Delfos · Barcelona, SpainContact R•••@startresearch.com→none listed
  • ICO Hospitale · Barcelona, SpainContact m•••@iconcologia.net→none listed
  • Vall D'Hebron University Hospital · Barcelona, SpainContact s•••@vhio.net→none listed
  • HM Sanchinarro · Madrid, SpainContact j•••@startmadrid.com→none listed
  • Hospital 12 de Octubre · Madrid, SpainContact j•••@h12o.es→none listed
  • START Madrid FJD · Madrid, SpainContact v•••@startmadrid.com→none listed
  • Ospedale Regionale Bellinzona · Bellinzona, SwitzerlandContact m•••@eoc.ch→none listed
  • Leicester Royal Infirmary · Leicester, United KingdomContact h•••@nhs.net→none listed
  • Royal Marsden Hospital · London, United KingdomContact S•••@rmh.nhs.uk→l•••@rmh.nhs.uk
  • University Hospital Southampton · Southampton, United KingdomContact i•••@soton.ac.uk→none listed
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Site contacts Changed at 22 sites. See the sites
    Show 22 sites
    • Valkyrie Clinical Trials · Los Angeles, United StatesContact d•••@valkyrieclinicaltrials.com→none listed
    • UC Irvine Health · Orange, United StatesContact f•••@hs.uci.edu→none listed
    • START Dallas-Fort Worth · Fort Worth, United StatesContact h•••@txcc.com→none listed
    • NEXT Oncology Virginia · Fairfax, United StatesContact a•••@nextoncology.com→none listed
    • Aalborg Universitets hospital · Aalborg, DenmarkContact w•••@rn.dk→none listed
    • Rigshospitalet University · Copenhagen, DenmarkContact k•••@regionh.dk→none listed
    • Helsinki University Hospital · Helsinki, FinlandContact k•••@hus.fi→none listed
    • Turku University Hospital · Turku, FinlandContact p•••@utu.fi→none listed
    • Institut Bergonie · Bordeaux, FranceContact v•••@bordeaux.unicancer.fr→none listed
    • Marseille University Hospital Timone · Marseille, FranceContact l•••@ap-hm.fr→none listed
    • CHU de Poitiers · Poitiers, FranceContact n•••@chu-poitiers.fr→none listed
    • Gustave Roussy · Villejuif, FranceContact a•••@gustaveroussy.fr→none listed
    • HM Nou Delfos · Barcelona, SpainContact R•••@startresearch.com→none listed
    • ICO Hospitale · Barcelona, SpainContact m•••@iconcologia.net→none listed
    • Vall D'Hebron University Hospital · Barcelona, SpainContact s•••@vhio.net→none listed
    • HM Sanchinarro · Madrid, SpainContact j•••@startmadrid.com→none listed
    • Hospital 12 de Octubre · Madrid, SpainContact j•••@h12o.es→none listed
    • START Madrid FJD · Madrid, SpainContact v•••@startmadrid.com→none listed
    • Ospedale Regionale Bellinzona · Bellinzona, SwitzerlandContact m•••@eoc.ch→none listed
    • Leicester Royal Infirmary · Leicester, United KingdomContact h•••@nhs.net→none listed
    • Royal Marsden Hospital · London, United KingdomContact S•••@rmh.nhs.uk→l•••@rmh.nhs.uk
    • University Hospital Southampton · Southampton, United KingdomContact i•••@soton.ac.uk→none listed
  2. Oct 22, 2026
    21 sites added — first sites in Denmark, Finland, France, Spain, Switzerland and 1 more
    All 6 countries

    Denmark, Finland, France, Spain, Switzerland, United Kingdom

    Show 21 added (6 Spain, 4 France, 3 United States, 3 United Kingdom, 2 Denmark, 2 Finland, 1 Switzerland)
    • Valkyrie Clinical Trials · Los Angeles, United States
    • UC Irvine Health · Orange, United States
    • START Dallas-Fort Worth · Fort Worth, United States
    • Aalborg Universitets hospital · Aalborg, Denmark
    • Rigshospitalet University · Copenhagen, Denmark
    • Helsinki University Hospital · Helsinki, Finland
    • Turku University Hospital · Turku, Finland
    • Institut Bergonie · Bordeaux, France
    • Marseille University Hospital Timone · Marseille, France
    • CHU de Poitiers · Poitiers, France
    • Gustave Roussy · Villejuif, France
    • HM Nou Delfos · Barcelona, Spain
    • ICO Hospitale · Barcelona, Spain
    • Vall D'Hebron University Hospital · Barcelona, Spain
    • HM Sanchinarro · Madrid, Spain
    • Hospital 12 de Octubre · Madrid, Spain
    • START Madrid FJD · Madrid, Spain
    • Ospedale Regionale Bellinzona · Bellinzona, Switzerland
    • Leicester Royal Infirmary · Leicester, United Kingdom
    • Royal Marsden Hospital · London, United Kingdom
    • University Hospital Southampton · Southampton, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07563738
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Mar 27, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Clinical Study Director
Contact
clinicaltrials@orionpharma.com
+358104261

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion